Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

9/10/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRNS alert in real time by email

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.

A link to the event can be accessed on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY^® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910315715/en/

Get the next $MRNS alert in real time by email

Date	Price Target	Rating	Analyst
9/23/2024	$6.00	Perform → Outperform	Oppenheimer
8/14/2024		Buy → Neutral	Ladenburg Thalmann
4/16/2024	$20.00 → $2.00	Outperform → Neutral	Robert W. Baird
4/15/2024	$24.00 → $3.00	Outperform → Sector Perform	RBC Capital Mkts
8/11/2023	$14.00 → $9.00	Outperform → Perform	Oppenheimer
1/20/2023	$23.00	Outperform	RBC Capital Mkts
12/20/2021	$32.00 → $30.00	Outperform	SVB Leerink

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $MRNS

$MRNS Market Insights

Live Market Insights

China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder

Truist Securities Maintains Buy on Marinus Pharma, Maintains $10 Price Target

HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $11 Price Target

$MRNS Press Releases

Fastest customizable press release news feed in the world

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

$MRNS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

$MRNS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

$MRNS SEC Filings

Marinus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MRNS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mayleben Timothy M gifted 8,300 shares (SEC Form 4)

CHIEF MEDICAL OFFICER Hulihan Joseph sold $5,456 worth of shares (4,828 units at $1.13), decreasing direct ownership by 6% to 72,725 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Shafer Christina sold $4,355 worth of shares (3,820 units at $1.14), decreasing direct ownership by 5% to 67,406 units (SEC Form 4)

$MRNS Financials

Live finance-specific insights

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

$MRNS Leadership Updates

Live Leadership Updates

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

Recent Analyst Ratings for
$MRNS

$MRNS
Market Insights

$MRNS
Press Releases

$MRNS
Analyst Ratings

$MRNS
Large Ownership Changes

$MRNS
SEC Filings

$MRNS
Insider Trading

$MRNS
Financials

$MRNS
Leadership Updates